Main Research Findings

1) Allosteric modulation of the sigma-1 receptor SOMCL-668 was found to elicit antipsychotic-like effects.

2) The sigma-1 receptor SOMCL-668 was found to rapidly promote antidepressant effects through allosteric modulation.

Selected Data
1) The study performed by the research team of Chen et al employed a comprehensive experimental design combining behavioral, pharmacological, electrophysiological, and molecular biology techniques to investigate the antipsychotic-like effects of the sigma-1 receptor allosteric modulator SOMCL-668. SOMCL-668, the primary compound under investigation, was synthesized in-house to a purity exceeding 98%. Additional pharmacological agents included PRE084, a selective sigma-1 receptor agonist, BD1047, a sigma-1 receptor antagonist, LY294002, a PI3K/AKT pathway inhibitor, and phencyclidine, PCP, which was used to induce schizophrenia-like behaviors in mice. These compounds were administered at specific doses and schedules, with detailed protocols provided in supplementary materials [1].
Behavioral assessments formed a central component of the methodology. Several validated paradigms were used to model schizophrenia-related symptoms. Prepulse inhibition (PPI) was used to measure sensorimotor gating deficits, while locomotor activity assays assessed hyperactivity induced by acute PCP administration. For chronic models, social interaction (SI) tests evaluated negative symptom-like behaviors, and novel object recognition (NOR) tests assessed cognitive function. These behavioral assays were conducted using standardized procedures previously established in the literature, ensuring reproducibility and comparability across studies.
To complement behavioral analyses, electrophysiological experiments were conducted using acute brain slice preparations from young mice aged 2–3 weeks. Animals were anesthetized and brain tissue was rapidly extracted and preserved in ice-cold solutions. Whole-cell patch-clamp recordings were performed on layer 2/3 pyramidal neurons in the cortex using a HEKA EPC-10 amplifier. These experiments examined neuronal excitability and intrinsic plasticity by measuring parameters such as rheobase, the minimum current required to evoke action potentials, and spike frequency responses under different pharmacological conditions. SOMCL-668 and PRE084 were applied individually and in combination to evaluate potential allosteric interactions at the sigma-1 receptor [1].
Molecular analyses were carried out using western blotting to quantify protein expression levels associated with intracellular signaling pathways. Brain tissues were homogenized and lysed, and protein samples ranging from 40–80 μg were separated via SDS-PAGE before transfer to nitrocellulose membranes. The membranes were probed with antibodies targeting key proteins, including sigma-1 receptor, phosphorylated and total AKT, phosphorylated and total CREB, and brain-derived neurotrophic factor (BDNF). α-tubulin served as a loading control. Detection was performed using chemiluminescence, and quantitative analysis of protein bands was conducted using ImageJ software [1].
The study also incorporated genetic approaches using sigma-1 receptor knockout mice to verify receptor-specific mechanisms. These knockout animals were compared with wild-type controls across behavioral and molecular experiments to determine whether the observed effects of SOMCL-668 were dependent on sigma-1 receptor function. Additionally, pharmacological antagonism using BD1047 provided a complementary approach to validate receptor involvement. To further investigate intracellular signaling mechanisms, the PI3K/AKT pathway inhibitor LY294002 was used to disrupt downstream signaling and assess its role in mediating behavioral and molecular effects. This allowed the researchers to test whether activation of the AKT–CREB–BDNF pathway was necessary for the therapeutic-like effects of SOMCL-668.
Overall, the methods integrated behavioral neuroscience, electrophysiology, pharmacology, and molecular biology to provide a multidimensional assessment of SOMCL-668. This design enabled the researchers to link behavioral outcomes with underlying cellular and biochemical mechanisms, while also confirming receptor specificity through both pharmacological blockade and genetic deletion approaches [1].
2) The study conducted by Wang et al investigated the antidepressant-like effects and underlying mechanisms of the sigma-1 receptor allosteric modulator SOMCL-668 using a combination of in vivo behavioral assays, in vitro cellular experiments, and molecular analyses. The compound SOMCL-668 was synthesized with high purity and compared against established pharmacological agents including the sigma-1 receptor antagonist BD1047, the sigma-1 agonist PRE-084, and the clinically used antidepressant venlafaxine. All compounds were prepared in dimethyl sulfoxide and diluted appropriately for administration [2].
Male C57BL/6 mice aged 6–8 weeks were used for all behavioral experiments. Animals were housed under controlled environmental conditions with a standard light/dark cycle and given free access to food and water. All procedures adhered to ethical guidelines for animal research. The study employed several validated behavioral paradigms to assess depressive- and anxiety-like behaviors, including the forced swimming test (FST), tail suspension test (TST), open field test, and the chronic unpredictable mild stress (CUMS) model. In the acute behavioral assays (FST and TST), mice were randomly assigned to treatment groups receiving saline, varying doses of SOMCL-668 ranging between 5, 10, or 20 mg/kg, PRE-084, or venlafaxine. To confirm sigma-1 receptor involvement, some animals were pretreated with BD1047 prior to SOMCL-668 administration.
For modeling chronic depression, mice were subjected to an 8-week CUMS protocol consisting of randomized mild stressors. After depressive-like behaviors were established, animals received daily intraperitoneal injections of SOMCL-668 or venlafaxine. Behavioral outcomes were monitored weekly using the sucrose preference test to assess anhedonia, alongside measurements of body weight and locomotor activity.
To explore cellular mechanisms, the study utilized both immortalized HT22 hippocampal neuronal cells and primary cortical/hippocampal neurons derived from embryonic mice. Cells were cultured under standard conditions and subjected to pharmacological treatments including sigma-1 receptor agonists and SOMCL-668. Immunostaining techniques were used to examine the localization of sigma-1 receptors and their interaction with the endoplasmic reticulum chaperone Bip. Confocal microscopy allowed visualization of receptor translocation following drug treatment [2].
Neurite outgrowth assays were conducted in primary neurons to assess structural plasticity. Cells were treated for 48 hours and stained with MAP-2 antibodies to visualize neuronal processes. Quantification of neurite length was performed using ImageJ software, measuring at least 20 neurons per experiment across multiple replicates. In parallel, enzyme-linked immunosorbent assays were used to quantify BDNF levels in the culture media, providing a measure of neurotrophic activity.
To determine the role of sigma-1 receptors more directly, gene knockdown experiments were performed using small interfering RNA (siRNA) targeting the sigma-1 receptor in HT22 cells. Successful knockdown was achieved using Lipofectamine-mediated transfection, and downstream signaling effects were assessed following treatment [2].
Protein expression and signaling pathway activation were evaluated using Western blot analysis. Hippocampal tissue samples from treated mice, as well as cultured cells, were homogenized and analyzed for levels of BDNF, total and phosphorylated glycogen synthase kinase-3β (GSK3β), sigma-1 receptor, and Bip. Protein bands were visualized using chemiluminescence and quantified using densitometry. These assays were critical for examining the involvement of the BDNF–GSK3β signaling pathway in mediating antidepressant effects.
Statistical analyses were conducted using standard methods. Data were expressed as mean ± SEM. Comparisons between two groups were performed using Student’s t-test, while multiple group comparisons utilized one-way or two-way ANOVA followed by appropriate post hoc tests. Overall, the experimental design combined behavioral pharmacology, cellular neuroscience, and molecular biology techniques to comprehensively evaluate both the efficacy and mechanism of SOMCL-668 as a novel antidepressant agent [2].

Discussion
1) The results from the study conducted by Chen et al demonstrate that SOMCL-668 exerts robust antipsychotic-like effects across multiple behavioral, electrophysiological, and molecular domains, with strong evidence supporting a sigma-1 receptor-dependent mechanism. In acute behavioral models, SOMCL-668 significantly attenuated PCP-induced disruptions in prepulse inhibition (PPI), a widely used measure of sensorimotor gating deficits associated with schizophrenia. SOMCL-668 improved PPI in a dose-dependent manner at multiple prepulse intensities. Additionally, it reduced PCP-induced hyperlocomotion, indicating an ability to counteract positive symptom-like behaviors. The sigma-1 receptor agonist PRE084 produced similar effects, supporting the involvement of this receptor system. Importantly, neither compound altered baseline locomotion when administered alone, suggesting specificity for pathological conditions [1].
In chronic PCP models, SOMCL-668 also improved negative and cognitive symptoms. Chronic PCP reduced social interaction time and impaired performance in the novel object recognition (NOR) test. Treatment with SOMCL-668 restored social interaction and significantly improved both exploration time and discrimination index in NOR tasks. These improvements were dose-dependent and comparable to those observed with PRE084, further supporting a sigma-1 receptor-mediated effect.
Mechanistic studies confirmed that these behavioral effects were dependent on the sigma-1 receptor. Pretreatment with the antagonist BD1047 blocked the beneficial effects of SOMCL-668 on both PPI and locomotor activity. Similarly, in sigma-1 receptor knockout mice, SOMCL-668 failed to improve PCP-induced behavioral abnormalities, including deficits in PPI, hyperactivity, social interaction, and cognition. These findings provide strong evidence that the therapeutic-like effects of SOMCL-668 require functional sigma-1 receptors [1].
Electrophysiological experiments revealed that SOMCL-668 acts as a positive allosteric modulator of sigma-1 receptor function. While neither SOMCL-668 nor PRE084 alone significantly altered neuronal excitability measured by rheobase, PRE084 increased action potential firing in cortical pyramidal neurons. Notably, SOMCL-668 enhanced spike frequency adaptation and, when co-applied with PRE084, produced a leftward shift in the current–spike relationship. This indicates that SOMCL-668 amplifies the effects of sigma-1 receptor activation on intrinsic neuronal plasticity. These effects were absent in sigma-1 receptor knockout mice, further confirming receptor specificity.
In vivo experiments also demonstrated allosteric modulation. A low dose of SOMCL-668 that was ineffective on its own significantly enhanced the behavioral improvements produced by PRE084 in social interaction and cognitive tasks. This synergistic interaction provides additional evidence that SOMCL-668 functions as a positive allosteric modulator rather than a direct agonist.
At the molecular level, SOMCL-668 reversed PCP-induced reductions in brain-derived neurotrophic factor (BDNF) expression in the prefrontal cortex. Chronic PCP decreased BDNF levels, while SOMCL-668 restored them toward normal levels in wild-type mice. This effect was absent in sigma-1 receptor knockout mice, indicating that BDNF regulation is mediated through sigma-1 receptor activation. Further analysis revealed that SOMCL-668 also restored phosphorylation levels of AKT and CREB, key upstream regulators of BDNF expression. PCP reduced p-AKT/AKT and p-CREB/CREB ratios, and SOMCL-668 reversed these changes in wild-type but not knockout mice. This suggests that SOMCL-668 activates the AKT–CREB–BDNF signaling pathway through sigma-1 receptor modulation [1].
The role of this pathway was further validated using the PI3K/AKT inhibitor LY294002. Administration of LY294002 blocked the ability of SOMCL-668 to improve social and cognitive deficits, and also prevented the restoration of BDNF expression. Interestingly, LY294002 alone induced behavioral deficits similar to those caused by PCP, highlighting the importance of AKT–CREB–BDNF signaling in normal cognitive and social functioning.
Taken together, the results demonstrate that SOMCL-668 produces antipsychotic-like effects across multiple domains, including positive, negative, and cognitive symptoms. These effects are mediated by sigma-1 receptor activation and involve enhancement of neuronal plasticity and upregulation of the AKT–CREB–BDNF signaling pathway. The convergence of behavioral, electrophysiological, and molecular findings provides strong proof-of-concept evidence supporting sigma-1 receptor allosteric modulation as a promising therapeutic strategy for schizophrenia [1].
2) The results of the study conducted by Wang et al demonstrates that SOMCL-668 produces robust and rapid antidepressant-like effects through sigma-1 receptor-dependent mechanisms, involving modulation of the BDNF–GSK3β signaling pathway. Across multiple behavioral and molecular assays, the compound showed both acute and sustained efficacy [2].
In acute behavioral tests, SOMCL-668 significantly reduced immobility time in both the FST and TST, which are standard measures of antidepressant activity. Mice treated with SOMCL-668 exhibited dose-dependent reductions in immobility, with higher doses producing stronger effects. These reductions were comparable to those observed with PRE-084 and venlafaxine. Importantly, pretreatment with the sigma-1 receptor antagonist BD1047 abolished these effects, demonstrating that the antidepressant-like activity of SOMCL-668 is mediated specifically through sigma-1 receptor modulation. Additionally, locomotor activity was unaffected, indicating that the observed behavioral changes were not due to nonspecific increases in movement.
In the CUMS model, SOMCL-668 reversed depression-like phenotypes more rapidly than traditional antidepressants. CUMS significantly reduced sucrose preference, reflecting anhedonia, but treatment with SOMCL-668 restored sucrose consumption to near-control levels within one week. The compound also reversed stress-induced reductions in body weight gain and improved performance in the open field test, indicating reduced anxiety-like behavior. Notably, the onset of therapeutic effects occurred within 7 days, faster than the typical delayed response seen with venlafaxine [2].
At the molecular level, SOMCL-668 enhanced phosphorylation of GSK3β at serine-9 in the hippocampus, a modification associated with enzyme inactivation and antidepressant action. Both SOMCL-668 and PRE-084 increased pGSK3β levels, while BD1047 blocked this effect. In cultured HT22 cells, sigma-1 receptor activation by (+)SKF-10047 produced dose- and time-dependent increases in GSK3β phosphorylation, which were further potentiated by SOMCL-668. However, this enhancement was abolished when sigma-1 receptors were knocked down siRNA confirming receptor specificity.
Further investigation revealed that this signaling effect depends on the BDNF–TrkB–AKT pathway. BDNF treatment alone increased GSK3β phosphorylation, while inhibition of TrkB receptors or the PI3K/AKT pathway blocked sigma-1 receptor-mediated effects. These findings indicate that sigma-1 receptor activation leads to downstream signaling through neurotrophic pathways critical for antidepressant responses.
In the CUMS model, chronic stress reduced hippocampal BDNF expression and GSK3β phosphorylation, consistent with depressive pathology. SOMCL-668 treatment restored both BDNF levels and pGSK3β expression, whereas venlafaxine did not significantly reverse these molecular deficits within the same timeframe. Additionally, SOMCL-668 increased these markers even in naïve mice, suggesting a direct neurotrophic effect. The study also showed that CUMS decreased sigma-1 receptor expression in the hippocampus, and that SOMCL-668 treatment restored receptor levels. This suggests that sigma-1 receptor downregulation may contribute to depressive states and that its restoration is part of the therapeutic mechanism [2].
At the cellular level, SOMCL-668 demonstrated hallmark properties of an allosteric modulator. The compound alone did not induce sigma-1 receptor dissociation from Bip, but significantly enhanced the effect of the agonist (+)SKF-10047, promoting receptor translocation from the endoplasmic reticulum to the plasma membrane. This confirms that SOMCL-668 acts by potentiating receptor responses rather than directly activating them.
Finally, functional outcomes of this modulation were observed in primary neuron cultures. SOMCL-668 alone did not significantly affect neurite outgrowth or BDNF secretion, but markedly enhanced the effects of sigma-1 receptor agonists. This synergistic action supports the conclusion that SOMCL-668 amplifies endogenous or agonist-driven signaling, consistent with its role as an allosteric modulator. In summary, the results provide strong evidence that SOMCL-668 exerts rapid antidepressant effects through sigma-1 receptor-dependent mechanisms. These effects involve enhancement of neurotrophic signaling, inhibition of GSK3β activity, restoration of receptor expression, and promotion of neuronal plasticity. The findings highlight allosteric modulation of sigma-1 receptors as a promising strategy for developing fast-acting antidepressants [2].

Disclaimer

**LAB USE ONLY**
*This information is for educational purposes only and does not constitute medical advice. THE PRODUCTS DESCRIBED HEREIN ARE FOR RESEARCH USE ONLY. All clinical research must be conducted with oversight from the appropriate Institutional Review Board (IRB). All preclinical research must be conducted with oversight from the appropriate Institutional Animal Care and Use Committee (IACUC) following the guidelines of the Animal Welfare Act (AWA).

Citations

[1] Chen J, Li G, Qin P, et al. Allosteric Modulation of the Sigma-1 Receptor Elicits Antipsychotic-like Effects. Schizophr Bull. 2022;48(2):474-484. doi:10.1093/schbul/sbab137

[2] Wang Y, Guo L, Jiang HF, Zheng LT, Zhang A, Zhen XC. Allosteric Modulation of Sigma-1 Receptors Elicits Rapid Antidepressant Activity. CNS Neurosci Ther. 2016;22(5):368-377. doi:10.1111/cns.12502

SOMCL-668 is sold for laboratory research use only. Terms of sale apply. Not for human consumption, nor medical, veterinary, or household uses. Please familiarize yourself with our Terms & Conditions before ordering.